The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial

BACKGROUND: Simultaneous chemotherapy with vascular endothelial growth factor (VEGF) inhibition has not shown additional benefit over chemotherapy alone in advanced melanoma. We tested administration of the potent VEGF inhibitor axitinib followed by paclitaxel/carboplatin to determine whether enhanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Algazi, A P, Cha, E, Ortiz-Urda, S M, McCalmont, T, Bastian, B C, Hwang, J, Pampaloni, M H, Behr, S, Chong, K, Cortez, B, Quiroz, A, Coakley, F, Liu, S, Daud, A I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402449/
https://www.ncbi.nlm.nih.gov/pubmed/25867272
http://dx.doi.org/10.1038/bjc.2014.541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402449/
https://www.ncbi.nlm.nih.gov/pubmed/25867272
http://dx.doi.org/10.1038/bjc.2014.541

Ejemplares similares